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aBstraCt
Autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV) is a hereditary autoimmune disorder 
of the eye caused by mutations in the CAPN5 gene. It is characterized by non-specific uveitis in the anterior cham-
ber and vitreous leading to panuveitis, iris and retinal neovascularization, cystoid macular edema, abnormal retinal 
pigmentation, vitreous hemorrhage, intraocular fibrosis, membrane formation and tractional retinal detachment. 
ADNIV is a progressive disease leading to complete blindness despite of treatment. Confirmation is made by genetic 
analysis demonstrating mutations of the CAPN5 gene.
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introduCtion
Autosomal dominant neovascular inflammatory 
vitreoretinopathy (ADNIV) is a very rare, autoim-
mune uveitis belonging to inherited vitreoretinal 
dystrophies [1]. The disease is caused by the muta-
tions in the CAPN5 gene (calpain-5) [2, 3]. Ge-
netic locus for ADNIV was mapped to chromosome 
11q13 in 1992 by Stone et al. [4, 5]. This gene 
encodes a protein, calpain-5, which is an intracel-
lular calcium-activated cysteine protease [2, 3, 6]. 
CAPN5 is the first nonsyndromic gene for autoim-
mune uveitis and among the very few Mendelian 
autoimmune diseases where the gene is identified 
[6]. There is significant phenotypic variance in AD-
NIV causes by different mutations in CAPN5 gene. 
Recent genetic tests have discovered two new muta-
tions which were described in literature in 2017 [7].
The first scientific work describing ADNIV was 
published in 1990 by Steven Bennett and co-work-
ers. The authors presented symptoms and causes of 
the illness illustrated with an example of large group 
of affected 28 of 61 members of a six generation 
family [8]. The ADNIV occurs with a frequency 
of approximately one in 1 000 000 births and has 
been found worldwide [9]. The pathophysiology 
and immunopathology are not yet well known. The 
first symptoms can occur at all ages [9]. The disease 
is very progressive despite the treatment and leading 
to complete blindness.
Loss of the b-wave amplitude on electroretinog-
raphy (ERG) is a characteristic feature of ADNIV 
disease [8].
The pathophysiology of the illness has not been 
known well; therefore, the condition is given a de-
scriptive name autosomal dominant neovascular in-
flammatory vitreoretinopathy.
diagnosis
The diagnosis of the disease is difficult due to 
several causes. Firstly, ADNIV is classified as a rare 
disease; secondly, the first signs can occur at any 
age and cannot be detected in childhood; there-
fore, unfortunately, the diagnosis is delayed in most 
cases. The symptoms of the disorder mimic sev-
eral much more common eye diseases, including 
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non-specific uveitis, retinitis pigmentosa, rod-cone 
dystrophy, proliferative diabetic retinopathy and 
proliferative vitreoretinopathy [8]. Because of its 
similarity to these disorders, ADNIV patients are 
often misdiagnosed. The very characteristic sign of 
the ADNIV is a lack of systemic features unlike in 
some of the disorders mentioned above [1]. It is 
important sign in differential diagnosis.
The family history is very important because 
helps to recognize hereditary nature of the disease 
and suggests a genetic etiology. If the patient lacks 
a family history of ADNIV and presents with vitre-
ous inflammation, a thorough evaluation for infec-
tious and inflammatory etiologies should be per-
formed [10].
Key findings in correct diagnosis are molecular 
genetic examination and ERG testing. ADNIV is 
inherited in an autosomal dominant manner. It 
means that each child has a 50% chance of inher-
iting the condition from an affected parent. It is 
present in every generation of affected family. The 
disease is caused by the mutations in CAPN5 gene 
localized on chromosome 11q13. 
Best’s vitelliform dystrophy, another disease in-
herited in autosomal dominant manner, is caused 
by the gene mutation mapped also to chromosome 
11q13 [11]. We do not know yet, whether there are 
any other common features with ADNIV disease.
Different molecular genetic testing is necessary 
to detect mutations. If there is no possibility to con-
duct comprehensive genetic testing, the diagnosis of 
ADNIV unfortunately is delayed.
Retinal degeneration in ADNIV patients can 
be detected by examining fundus autofluorescence 
(FAF) and infrared reflectance (IR) of the fun-
dus. The fundus displays enhanced FAF observed 
during mid-to-late stage ADNIV and is associated 
with photoreceptor or RPE cell dysfunction. IR 
imaging of the retina shows pigmentary changes in-
dicative of reactive retinal pigment epithelium cells 
and photoreceptor degeneration [12].
Another important examination confirming the 
diagnosis of the disease is ERG testing. The abnor-
mality is detectable with electroretinography very 
early in the course of the disease despite the nor-
mal appearing of the retina. ERG signaling defects 
precedes the signs of photoreceptors degeneration 
[13]. In early stages, we observe a reduced b-wave 
on ERG, later it is selective loss of the b-wave in the 
scotopic bright flash [3]. This indicates dysfunc-
tion of signal transmission from photoreceptors to 
membranes of the inner retina such as bipolar cells 
due to localization of CAPN5 to the photoreceptor 
synapse [10]. With progression of the disease there 
is also a reduction of the a-wave and in the last stage 
the ERG is extinguished; it shows non-recordable 
cone and rod responses due to severe photoreceptor 
dysfunction [2, 3].
Genetic analysis or ERG testing is performed in 
patients who do not demonstrate classic features of 
ADNIV or those who are younger than 30 years of 
age [10].
syMptoMs
There are 5 stages in the course of ADNIV, each 
lasting approximately ten years.
The first stage begins in the second or third dec-
ade of life and is asymptomatic for the patient. In 
the first stage we observe inflammatory cells in the 
vitreous, minimal far peripheral arteriolar closure, 
pigmentation and mild peripheral ischemia. In this 
stage, ADNIV is clinically indistinguishable from 
an autoimmune, non-infectious uveitis.
The electroretinogram demonstrates early retinal 
and photoreceptor dysfunction. The most character-
ized feature is reduction of b-wave.
In the second stage, patients become sympto-
matic, the anterior chamber shows mild inflamma-
tory cells and there is early development of cata-
ract. The inflammatory cells are still observed in the 
vitreous. The posterior segment shows pigmentary 
retinal degeneration and some macular and optic 
nerve head edema.
Stage three of the disease usually develops during 
the third or fourth decades, but in some cases can 
start earlier [14]. There are moderate inflammatory 
cells, progressive cataract and iris synechiae. Some-
times peripheral iris stromal atrophy and thinning 
occur. Development of band keratopathy is some-
times seen in the patients. The posterior segment 
shows cystoid macula edema (Fig. 1AB), progressive 
vascular closure with neovascularization of the far 
peripheral retina or optic disc. With the develop-
ment of inflammation in the vitreous, epiretinal and 
subretinal membranes start to develop (Fig. 2AB). 
There are extensive pigmentary and atrophic chang-
es throughout the fundus. Optical coherence tom-
ography reveals distortion of the retinal layers. There 
is a decline of peripheral vision with progressively 
constricted visual field, which indicates reduced 
retinal light sensitivity. In some cases despite of the 
significant disease progression, the limited central 
vision is observed [14].
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In stage four neovascular and angle closure 
glaucoma caused by inflammation in the anterior 
chamber is observed; next, epiretinal membranes 
formation and proliferative vitreoretinopathy 
starts. Profound visual loss is due to ongoing neo-
vascularization of the retina that causes vitreous 
hemorrhage, tractional retinal detachment and neo-
vascular glaucoma. In the last fifth stage, the eyes 
become hypotonous and subsequently phthisical, 
leading to complete blindness.
Patients with ADNIV have night blindness only 
as a very late manifestation of the disease. There is 
no evidence for systemic autoimmune or systemic 
inflammatory conditions in ADNIV patients.
The development of secondary glaucoma is ob-
served in ADNIV patients. The IOP management is 
connected with uveitic glaucoma, steroid-response 
glaucoma, angle closure glaucoma and hypotony. 
The chronic uveitis can cause aqueous hyposecre-
tion, due to inflammation of the ciliary body, but 
this IOP-lowering effect is usually overpowered by 
the increased resistance to trabecular drainage from 
inflammatory infiltrates and endothelial dysfunc-
tion [15]. Necessary steroids therapy is the result of 
a B
Figure 1aB. Optical coherence tomography (OCT) presenting cystoid macular edema (CME) in patients with autosomal dominant neo-
vascular inflammatory vitreoretinopathy
Figure 2aB. Fundus images showing vitritis in a patient with autosomal dominant neovascular inflammatory vitreoretinopathy
a B
OphthalmOlOgy JOurnal 2019, Vol. 4
18 www.journals.viamedica.pl/ophthalmology_journal
steroid-induced glaucoma. Furthermore, develop-
ment of neovascularization in the anterior chamber 
causes angle closure glaucoma. In late stages, some 
ADNIV eyes become hypotonous [15]. Interesting-
ly, some ADNIV patients do not develop elevated 
IOP or glaucoma despite decades of ADNIV and 
steroid therapy.
The rate of disease progression, specific features 
and vision loss vary between the affected members 
of a given family and is also asymmetrical between 
eyes. For example, some of the ADNIV patients 
develop blindness in one eye before the other, re-
maining partially sighted for years [16].
pathophysiology
Autosomal dominant neovascular inflammatory 
vitreoretinopathy is also an autoimmune disorder 
but pathophysiology and immunopathology is not 
well known. Immunohistological stain revealed T-
cell infiltrated in ADNIV patients; hence, there 
is a suggestion that T-cell may play main role in 
immunopathology of the disease [17]. No specific 
antibodies were detected in ADNIV patients so far. 
It was noted that despite organ atrophy in the late 
stages of the disease, antigen reactions may still be 
active. The phthisis in the ADNIV eye seems to 
be immunologically different from that observed 
in eyes with phthisis from other conditions [17]. 
It is reported that cell-mediated rather than anti-
body-mediated autoimmunity may be the primary 
inflammatory mechanism [17]. Studies of human 
autopsy eyes indicated that ADNIV uveitis is pri-
marily driven by cell-mediated immunity [12]. The 
vitreous biopsy revealed that interleukin-6 was el-
evated, suggesting a stimulated inflammatory or 
autoimmune response [12].
The physiologic role of calpain-5 is not well 
known. Calpain-5 was found to be located in the 
inner and outer segments of the photoreceptor 
cells and also within the outer plexiform layer 
[13]. The mutations alter its location inside the 
cells and probably its proteolytic activity or spe-
cificity. So CAPN5 could account for the various 
inflammatory degenerations, vascular and fibrotic 
phenotypes observed in ADNIV patients. Wert et 
al. report that the effect of the ADNIV mutation 
is to increase CAPN5 catalytic activity. This insight 
was next supported by physiologic testing of the 
CAPN5(R243) mutation in vivo [12]. Increased 
calpain activity is a feature of many eye-related 
pathologies including retinal degeneration, retinal 
hypoxia, retinitis pigmentosa, retinal detachment 
and glaucoma [18]. Retinal damage from these 
pathologies can be lessened by administering the 
calpain inhibitor SJA6017, but it is not known 
which isoform(s) exert(s) an inhibitory effect [18]. 
CAPN5 is widely expressed in the human body in 
the colon, kidney, liver, trachea, uterus, eye and 
brain, but the ADNIV is restricted just to the eye 
[13]. Retinal expression of CAPN5 may be suffi-
cient to generate an autoimmune response. Study 
of CAPN5 mutations can provide insight into 
mechanisms of this disease and help us develop 
treatments for ADNIV and more common eye dis-
eases with inflammation and neovascularization. 
Calpains have been implicated in the pathogen-
esis of different diseases including cancer, multiple 
sclerosis, Alzheimer’s disease, cataract, diabetes and 
muscular dystrophy [3]. Several human neuro-
logical disorders have been associated with excess 
calpain activity. Wort et al. generated transgenic 
mice expressing human CAPN5(R243L) only in 
the retina and observed a clinical, histologic and 
molecular phenotype consistent with human AD-
NIV [12]. This mouse model can be used to ex-
plore protease mechanism, disease progression and 
possible therapies and have utility for other types 
of uveitis.
Uveitis in ADNIV is characterized by infiltrating 
CD3+ and CD4+ inflammatory cells in the vitreous, 
the uvea and the retina, suggesting a predominantly 
T-cell process [13, 6]. Mutation in calpain-5 causes 
both early CD3+, T-cell migration into the retina 
and reduction in ERG b-wave amplitudes and later 
photoreceptors degeneration.
The Mahajan et al. described enucleated eye of 
ADNIV patient due to phthisis and pain. Exami-
nation of the enucleated eye revealed a shrunken 
distorted phthisical globe. The intraocular con-
tents were grossly disorganized. A segment of optic 
nerve was unremarkable. The cornea was depressed, 
brown and opaque, anterior chamber filled with 
hemorrhage. The posterior segment showed a vit-
reous filled with a red-brown material, a detached 
retina and subretinal hemorrhage. The optic nerve 
was atrophic with replacement of axons with colla-
genous bands. The iridocorneal angle was occluded 
by fibrous membranes. The retina showed extensive 
degeneration and retinal pigment epithelium sig-
nificant cell loss [6].
Despite organ atrophy in the late stages of dis-
ease, antigens that instigate autoimmune reactions 
may still be active. The ADNIV autoimmune reac-
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tion continues through end-stage disease when the 
eye becomes shrunken and blind [17].
The molecular mechanisms that initiate neuroin-
flammation are poorly understood.
Immunological mechanisms in the eye are also 
poorly understood.
diffeRential diagnosis
The differential diagnosis should include au-
toimmune uveitis, retinitis pigmentosa, rod-cone 
dystrophy, proliferative vitreoretinopathy and dia-
betic retinopathy [8, 13, 19, 20]. At different stag-
es ADNIV mimics this diseases but most of them 
are characterized with systemic features otherwise 
then in ADNIV. Comparing neovascularization 
seen in proliferative diabetic retinopathy and AD-
NIV, significant capillary dropout or evidence of 
ischemia is absent in ADNIV. This suggests that 
a non-ischemic signaling pathway activates neo-
vascularization. There is not a crisp demarcation 
line of vascular closure in the peripheral retina 
as can be seen in other peripheral retinal vascular 
diseases [8].
Retinal pigmentation in ADNIV begins in the 
area of vascular closure and becomes large deep 
round spots rather than the bone spicule pattern in 
the midperiphery seen in retinitis pigmentosa.
Another disease to be considered in the dif-
ferential diagnosis is familial exudative vitreoretin-
opathy. In this condition, we observe abrupt termi-
nation of the retinal vessels at the equator. Vessels 
probably never develop normally. In contrast, AD-
NIV patients initially have normal vessels which 
gradually become occluded. Another difference is 
absence of vitreous cells and loss of the b-wave on 
ERG testing in patients with familial exudative 
vitreoretinopathy [8].
There are other conditions in which we observe 
a selective loss of the b-wave, including retinal vas-
cular diseases such as central retinal artery or vein 
occlusions, quinine and methanol intoxication and 
siderosis. Inherited conditions in which the b-wave 
is affected include X-linked retinoschisis, myotonic 
dystrophy and forms of nonprogressive night blind-
ness [8].
Autosomal dominant neovascular inflammatory 
vitreoretinopathy is a unique eye disease, because it 
shows pathological symptoms of several eye diseases 
that normally do not occur together. Recognition 
of familial nature of ADNIV is very helpful to di-
agnose properly.
The disorder is dominant, highly penetrant and 
displays severe and different phenotype. Phenotypic 
discordance may be due to epigenetic, postzygotic 
or environmental differences [16].
treatment
Treatment of ADNIV patients is very difficult 
and many of them are refractory to it. One of the 
major reasons is a chronic, severe and non-specific 
autoimmune uveitis in the course of ADNIV. An-
other reason is iris and retina neovascularization 
leading to hemorrhage and fibrosis causing trac-
tional retinal detachment and ongoing outer reti-
nal degeneration.
Uveitis accounts for as much as 10–15% of 
blindness in the USA and is the fifth leading cause 
of vision loss in developed world. The manage-
ment of uveitis is often ineffective especially in 
non-specific uveitis, like in ADNIV patients [14]. 
Immunohistopathological findings suggest that un-
derlying ocular immune dysfunction is present. The 
treatment should be directed at major causes of 
profound vision loss such as photoreceptor degen-
eration, cataract, cystoid macular edema, vitreous 
hemorrhage, dense membrane formation leading 
to tractional retinal detachment, neovascular and 
steroid-responsive glaucoma.
Initial proceeding of ADNIV is directed to 
reduce active inflammation in anterior and pos-
terior segment and prevent serious complication 
of ongoing inflammation and neovascularization. 
The therapy of ADNIV involves steroids including 
topical, periocular and intravitreal injections. Long 
term local and systemic therapies are limited be-
cause of the numerous side effects like cataracts, 
infections and glaucoma. Periocular and intrav-
itreal steroids require injections at regular inter-
vals in order to control inflammation and cystoid 
macula edema. Some authors report the benefit 
of the fluocinolone acetonide (FA) implant in the 
treatment of chronic uveitis in ADNIV patients 
[14]. It provides continuous release of intraocular 
corticosteroid for approximately 2.5 years. It is 
surgically implanted through the pars plana into 
the vitreous and sutured to the sclera. FA implant 
reduces inflammation, neovascularization and, 
which is important, the need for systemic or lo-
cal therapy, but it does not stabilize long-term 
vision, retinal thickening and fibrosis [21]. The 
corticosteroid therapy in ADNIV is a non-specific 
therapy. Like some other uveitic conditions, AD-
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NIV eventually becomes resistant to conventional 
steroid immunosuppression.
This nonspecific therapy might be optimized 
by medications directed at the specific mediators of 
ADNIV. One study suggests that therapeutic strate-
gies targeting T cells may be more effective than 
nonspecific therapy. For example drugs such as cy-
closporin A, FK06, anti-CD3 and rapamycin that 
target T cell activation and downstream T cell path-
ways might have greater effect than B cell drugs such 
as cyclosphamide and mycophenylate mofetil [17].
 Treatment of ongoing iris and retinal neovas-
cularization apart from steroids therapy includes 
also anti-VEGF medication. Some authors reported 
applying of bevacizumab for recurrent uveitis [15]. 
The laser photocoagulation of the peripheral retina 
is only partially effective. Likewise, vitrectomy sur-
gery is related to recurrent membranes and detach-
ments.
ADNIV patients could be candidates for retinal 
gene therapy, but if disease allele expression in the 
eye is not sufficient, therapies directed to cells out-
side the eye as calpain-5 expressing T-cells might be 
required [13].
There is no therapy for retinal degeneration and 
there are no specific therapies for calpains [13]. To 
develop specific treatment for ADNIV an animal 
model is needed [13].
The development of secondary glaucoma is asso-
ciated with the need of applying antiglaucoma ther-
apy. Management of glaucoma in ADNIV patients 
can be challenging. Antiglaucoma medications in-
clude topical medication, surgeries like trabeculec-
tomy, Ahmed glaucoma valve surgery. Some authors 
report better results performing AGV concurrent 
with the FA implantation [15].
Maybe earlier therapy with T-cell immunomod-
ulators will be more successful. Specific therapy may 
delay or reverse symptoms in ADNIV and also in 
related eye diseases.
Untreated or under-treated patients have very 
poor prognosis.
ConClusion
Autosomal dominant neovascular inflamma-
tory vitreoretinopathy is a complex hereditary au-
toimmune disorder. The disease management poses 
several challenges like diagnosis, follow-up and in 
particular treatment. Recognition of the condition 
is important because it allows proper genetic coun-
selling and prevents unnecessary diagnostic investi-
gations. Despite the aggressive treatment the visual 
improvement is only transient — as the disease 
progresses patients progressively lose vision. AD-
NIV patients need careful, continuous long-term 
follow-up to address ongoing chronic inflamma-
tion, membrane formation, neovascularization and 
retinal degeneration. 
To better understand ADNIV pathogenesis fur-
ther investigations including immunology, physiol-
ogy and genetic are necessary.
Immunohistopathological findings suggest that 
an underlying ocular immune dysfunction is present 
in ADNIV patients. The creation of a pre-clinical 
model of ADNIV could be used to study mecha-
nisms of ADNIV disease progression and therapy.
Further study of mechanisms of ADNIV will 
provide important new insight into some of the 
most important causes of irreversible human blind-
ness, such as autoimmune uveitis, retinitis pigmen-
tosa, proliferative vitreoretinopathy and diabetic 
retinopathy. In-depth investigation of this disorder 
will hopefully lead to better understanding of its 
pathogenesis and ultimately result in effective treat-
ment.
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